A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Breast11
- Sponsors AstraZeneca; AstraZeneca AB
- 26 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2023 Planned End Date changed from 26 Jun 2026 to 30 Apr 2027.
- 26 Sep 2023 Planned primary completion date changed from 25 Dec 2023 to 20 Dec 2024.